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Objectives: We evaluated the in vivo performance of a newly devised vascular endothelial growth factor (VEGF)‐
bound stent in a porcine coronary model.
Background: An anti‐CD34 antibody‐bound stent, which captures endothelial progenitor cells (EPCs) to accelerate
tissue formation, did not reduce intimal hyperplasia. By targeting the VEGF receptor, which is expressed on
endothelial‐lineage cells, we developed VEGF‐bound stents that may enable selective capture of EPCs followed by
rapid endothelialization.
Methods: Metallic stents were ﬁrst coated with poly‐(ethylene‐co‐vinyl alcohol), and then chemically bound with
either VEGF or anti‐CD34 antibody. These stents were placed in porcine coronary arteries for up to 14 days. Stent
surface was evaluated by immunohistochemistry and by scanning electron microscope (SEM).
Results: After 2‐day stenting with VEGF‐bound stents, small populations of KDR (VEGF receptor‐2)‐positive cells
adhered to the stent struts. After 7‐ and 14‐day stenting, struts were fully covered with newly regenerated tissue. SEM
images showed that the uniform tissue formed on struts was morphologically similar to native endothelium and was
continuously connected with adjacent native endothelium. On the other hand, for the anti‐CD34 antibody‐bound
stents, stent struts were rapidly covered by newly generated tissue that consisted of multicellular aggregates.
Conclusions: Compared with anti‐CD34 antibody‐bound stents, VEGF‐bound stents provide highly selective
capture of EPCs, followed by rapid formation of intact endothelium tissue at an early period of stenting. These
results suggest that VEGF‐bound stents could represent a promising therapeutic option for cardiovascular stenting,
although further long‐term follow‐up experiment with double‐blinded fashion is needed prior to clinical application.
(J Interven Cardiol 2014;27:63–72)
Introduction
Drug‐eluting stents (DESs) have shown dramatic
efﬁcacy in reducing neointimal hyperplasia through
inhibition of smooth‐muscle cell proliferation at an
early period of stenting.1–3 However, major drawbacks
of DES include delayed formation of a functional
monolayer of endothelial cells (ECs) over the stent,
abrupt thrombus formation, and restenosis due to
in‐stent neointimal tissue hyperplasia in later periods of
stenting.4–8 One logical solution to avoiding these
drawbacks is to develop a system that promotes rapid
regeneration of a functional endothelium on the stent.
Endothelial progenitor cells (EPCs) circulating in
arterial blood ﬂow can adhere and differentiate into
mature ECs at sites of injured vessels, thereby
enhancing reendothelialization and restoring endothe-
lial function.9–11 Therefore, rapid and selective capture
of EPCs on the stent struts could avoid thrombus
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formation and reduce neointimal hyperplasia. EPCs
constitute a minor fraction of CD34‐expressing cells. A
recently developed EPC‐caputuring stent which sur-
face was coated with anti‐CD34 antibody accelerated
tissue formation and failed to reduce the following
intimal hyperplasia.12 Although no report has
described the cell types on such stents, various cell
types of CD34‐positive mononuclear cells other than
EPCs may adhere.13,14 This could adversely affect the
integrity of the tissue architecture as well as the
function of any ECs present. Therefore, it is unclear
whether CD34 is the best marker for cells with
capturing, differentiating, and endothelializing poten-
tial. Cell surface receptors exclusively expressed on
endothelial‐lineage cells include vascular endothelial
growth factor (VEGF) receptors and Tie molecules.
Our previous study of mononuclear cell culture on
surfaces coated with various types of proteins,
including antibodies to these receptors and VEGF,
showed that VEGF‐bound surfaces exhibit high
adhesion, proliferation, and differentiation poten-
tials.15,16 Based on these previous results, we devised
a new VEGF‐bound stent aiming at highly selective
capture of EPCs and rapid formation of intact
endothelium.15 In the current study, we report on the
in vivo performance of VEGF‐bound stents in an early
period of stenting (up to 2 weeks after coronary
implantation) in a porcine model, focusing especially
on whether EPCs were captured from local arterial
blood ﬂow by VEGF‐bound stents, and to what extent
endothelialization was achieved. We also compared
these outcomes with those noted in anti‐CD34
antibody‐bound stents. Both VEGF‐ and anti‐CD34
antibody‐bound stents were prepared in‐house accord-
ing to the same protocol.
Methods
Stents. Stents were made of cobalt–chromium
(kindly supplied by NIPRO Corp., Shiga, Japan) and
had the following dimensions: length, 8mm; diameter,
2.75–3.0mm in the deployed state; wall thickness,
75mm. Stents were coated with poly(ethylene‐co‐vinyl
alcohol) (68mole% of vinyl alcohol, 5mm thick) using
an ultrasonic atomizing spray–coating apparatus
(Sono‐Tek, Milton, NY, USA), followed by activation
of surface hydroxyl groups by N,N‐carbodiimidazole
in acetonitrile. Subsequently, the coated stents were
subjected to protein binding using either recombinant
VEGF165 (referred to as VEGF, purchased from
PeproTech, Rocky Hill, NJ, USA) or anti‐porcine
CD34 antibody (R&D Systems, Inc., Minneapolis,
MN, USA) in phosphate‐buffered saline (PBS) at room
temperature. The coated surfaces were smooth without
cracking and delamination upon deployment. The fully
saturated density of VEGF on the surface was
conﬁrmed at the protein‐binding step using the
relationship between ﬂuorescence intensity and ﬂuo-
rescently labeled protein concentration. The detailed
preparation and characterization procedures are
described in our previous article.15
Experimental Procedures. Animal experiments
were performed in compliance with the NIH Guide for
Care and Use of Laboratory Animals and Guidelines of
Kanazawa University School of Medicine. Domestic
female swine (N¼ 26, average weight 25 5 kg) were
used for implantation studies. Before each procedure,
animals were given 200mg aspirin (Bayer, Land
Nordrhein‐Westfalen, Germany) and 300mg clopidog-
rel (Sanoﬁ Aventis, Gouda, The Netherlands) as
loading doses, or 200mg aspirin and 75mg clopidogrel
daily until the end of the experiment. Each animal
received an intramuscular injection of ketamine
hydrochloride (20mg/kg) and was maintained under
general anesthesia with 2% halothane oxygen.
ECG, heart rate, and arterial blood pressure were
continuously monitored using a polygraph recording
system (OptiPlex755, Nihon‐Kohden, Tokyo, Japan)
throughout the entire procedure. A 6F‐guiding catheter
was advanced to the coronary artery through the left
carotid artery. A bolus of heparin (5,000 IU) was
administered intravenously, and an additional 2,000 IU
was injected every hour. We performed coronary
angiography using a cineangiography system (ARCA-
DIS Avantic, SIEMENS, Malvern, PA, USA). Under
guidance by intravascular ultrasound imaging (GAL-
AXY2 IVUS Imaging System, Boston Scientiﬁc,
Natick, MA, USA), VEGF‐bound or anti‐CD34
antibody‐bound stents were implanted into the proxi-
mal to mid portion of coronary arteries, with an
intended balloon–artery ratio of 1.1:1. The intravascu-
lar ultrasound observation was performed only for
conﬁrmation of complete stent a position at the time of
stent implantation. In the present study, the swine were
randomly implanted with same or different types of
stents. Animals were sacriﬁced 2 days (harvested
stents: 12 VEGF‐bound stents, 7 anti‐CD34 antibody‐
bound stents), 7 days (6 VEGF‐bound stents, 5 anti‐
CD34 antibody‐bound stents), or 14 days (13 VEGF‐
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bound stents, 15 anti‐CD34 antibody‐bound stents)
after implantation. In the present study, we did not
perform further long‐term observation because the
main purpose was to verify rapid capture of EPC at an
early period of stenting and accelerated endo-
thelialization.
Tissue Preparation. The coronary arteries, dis-
sected with a minimum of surrounding tissue, were
preserved for histological (N¼ 10) and immunohisto-
chemical (N¼ 17) examinations. Specimens were
ﬁxed for 24 hours with 20% formalin and embedded
in parafﬁn. For scanning electron microscope (SEM)
(N¼ 31), samples were ﬁxed for 2 hours with 2.0% (v/
v) glutaraldehyde in PBS and subsequently treated with
a series of dehydration steps using graded aqueous
solutions of 50%, 60%, 70%, 80%, 90%, 99%, and
100% ethanol for 10minutes at each step. Next,
samples were treated twice with 2‐methyl‐2‐propanol.
The samples were then frozen at 20 °C for 1 hour,
freeze‐dried for 2 hours in an ES‐2030 freeze dryer
(Hitachi High‐Technologies, Tokyo, Japan), and
sputter‐coated with osmium (VIII) oxide.
Morphometric and Histological Analysis. Par-
afﬁn‐embedded tissue was deparafﬁnized and then
stained immunohistochemically. VEGF receptor‐posi-
tive cells were evaluated by staining with an antibody
against KDR (07‐716, Merck Millipore, Darmstadt,
Germany) to detect endothelial‐lineage cells. These
specimens were rinsed with PBS and labeled with
Alexa Fluor 488‐conjugated goat anti‐rabbit IgG
antibody (A‐11029, Invitrogen, Carlsbad, CA, USA).
Nuclei were stained with Hoechst (33342 Dojin
Laboratories, Kumamoto, Japan) at a dilution ratio of
1:1,000. Immunoﬂuorescence images were obtained
using a BIOREVO ﬂuorescence microscope system
(BZ‐9000, Keyence, Osaka, Japan). After plastination
in Technovit 9100 methacrylate‐based resin (Heraeus-
Kulzer, Werheim, Germany), 5–6‐mm cross‐sections
were acquired from each stent using a Leica RM2145
rotary microtome (Leica Microsystems GmbH, Wet-
zlar, Germany). The specimens were stretched and
placed on prepared microscopic slides, and then stained
with hematoxylin–eosin (H–E). Neointimal thickness
was measured along a line perpendicular to the
neointima and top of the strut and between the strut
(total of 24 points were averaged). For immunohisto-
chemical staining of neointima, Ki67 (ab833, Abcam,
Cambridge, UK) was used as a proliferation marker;
proliferation activity was deﬁned quantitatively as the
proportion of Ki67‐positive cells in the neointimal area.
Digital microscope images were recorded on a VHX‐
500 (Keyence). SEM images were recorded on a
HITACHI SEM‐EDX (Hitachi‐Technologies) at an
acceleration voltage of 10 kV.
Statistics. All data are expressed as mean SD.
An unpaired t‐test was used for comparison between
the groups with VEGF‐bound stents and anti‐CD34
antibody‐bound stents. A P‐value of <0.05 was
considered statistically signiﬁcant.
Results
A total of 58 stents were implanted in the coronary
arteries of 26 swine: 22 VEGF‐bound stents for 11 swine
and 19 anti‐CD34 antibody‐bound stents for 9 swine. In
the remaining 6 swine, both VEGF‐ (n¼ 9) and anti‐
CD34 antibody‐ (n¼ 8) bound stents were implanted.
Thus, therewere a fewmixed types of stents deployment.
Under these conditions, expanded stent diameters
determined by intravascular ultrasound were 2.66
0.14mm in VEGF‐bound stents and 2.76 0.12mm
(NS) in anti‐CD34 antibody‐bound stents. All 58 stents
remained patent during the implantation period (up to
2 weeks) without evidence of stent thrombosis. Actually,
there were no problems during experimental procedures.
In the following sections, we describe representative
observations made on implanted stents.
VEGF‐Bound Stents. After 2 days of stenting
digital microscopy revealed that most of the strut
surface area was naked, whereas a smaller area was
covered by a thin layer of tissue (Fig. 1A). SEM images
revealed a small number of cells adherent to struts
(Fig. 1B–D). Most of these adherent cells, which were
not attached to native endothelium, immunostained
with anti‐KDR antibody (Fig. 2), indicating that
circulating EPCs were captured on stent struts in the
early period of stenting. At 7 days, strut surfaces were
completely covered by a thin layer of tissue, as revealed
by both digital microscopy and SEM (Fig. 3A and B).
Higher magniﬁcation SEM images showed that the
surfaces were fully covered by cells (Fig. 3C and D). At
14 days, struts were completely embedded in relatively
thick tissue (Fig. 4A). SEM images revealed that tissue
formed on struts was composed of endothelial‐like cells
with cobblestone morphology and was continuously
connected to adjacent native endothelium (Fig. 4B and
C). The tissue generated on strut surfaces was
approximately 20mm thick in this example
(Fig. 4D). Under these conditions, there still existed
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Figure 1. VEGF‐bound stent after 2‐day stenting. (A) Digital microscopic image showing naked and thin layer regions of the stent. (B–D) SEM
images showing adherent cells captured from the bloodstream.
Figure 2. Immunoﬂuorescence staining of adhered cells captured on the stent strut after 2‐day (A) and 14‐day (B) stenting. Left: anti‐KDR
antibody staining; center: nuclear staining (Hoechst, blue); right: merge.
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Figure 3. VEGF‐bound stent after 7‐day stenting. (A) Digital microscopic image showing the strut surface almost completely covered with a thin
layer of tissue. (B–D) SEM images showing complete coverage by endothelial‐like cells.
Figure 4. VEGF‐bound stent after 14‐day stenting. (A) Digital microscopic image showing that stents are completely embedded in a newly
generated tissue. (B and C) SEM images showing uniform endothelial tissue with cobblestone morphology. (D) SEM image of cross‐sectional
specimen. Note that intimal tissue on stent strut is approximately 20mm thick.
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KDR‐positive cells located within stent struts as well as
adjacent vascular tissue (Fig. 2).
Anti‐CD34 Antibody‐Bound Stents. After
2 days of stenting the surfaces of anti‐CD34
antibody‐bound stents were completely covered by
regenerated tissue (Fig. 5A), which was composed of
multicellular aggregates (Fig. 5B). At 7 days, the stents
were completely embedded in newly generated tissue
(Fig. 5C). SEM images revealed the presence of some
endothelial‐like cells, but for themost part multicellular
aggregates were observed (Fig. 5D). At 14 days, the
stent was embedded in thick tissue (Fig. 6A). SEM
images revealed that the tissue was of mixed types,
composed of both multicellular‐disorganized tissue
(Fig. 6B and C) and endothelium‐like tissue (Fig. 6D).
Neointimal Tissue: VEGF‐Bound Stents Versus
Anti‐CD34 Antibody‐Bound Stents. Interestingly,
proliferative cells detected by Ki67 (Fig. 7A) revealed
that the proportion of proliferating to total cells in the
neointimal tissue was much higher for the anti‐CD34
antibody‐bound stent (47.9 3.6%) than for the
VEGF‐bound stent (29.2 10.3%) (Fig. 7B). Indeed,
the average neointimal thickness of VEGF‐bound stent
was 67.9 30.5mm (Fig. 8A) andwas thinner than that
of the anti‐CD34 antibody‐bound stent with 79.8
28.7mm (Fig. 8B).
Discussion
The present study demonstrates that the newly
manufactured VEGF‐bound stents can selectively
capture KDR‐positive cells in the early phase after
deployment in porcine coronary arteries. Furthermore,
relatively smooth neointimal proliferation is observed
with less cellular activity than is noted in anti‐CD34
antibody‐bound stents. These results suggest that
VEGF‐bound stents can contribute to vital endothelial
architecture and may facilitate repair of diseased
coronary arteries. The DES has been widely used for
the treatment of coronary artery disease to reduce both
restenosis rates and target lesion revascularization.
However, recent clinical studies have shown that anti‐
proliferative drugs eluted from such stents often
interfere with the natural vascular healing process.17
To minimize or circumvent such events, recent efforts
have focused on capturing circulating EPCs onto stent
struts by biospeciﬁcally targeting EPCs with the cell
surface marker CD34, and EPCs have been detected in
the multicellular CD34‐positive fraction of mononu-
clear cells. In animal experiments, an anti‐CD34
antibody‐bound stent appeared to accelerate tissue
formation, but did not reduce neointimal thickness
compared with a noncoated bare metal stent.12 In
Figure 5. Anti‐CD34 antibody‐bound stents after 2‐day (A and B) and 7‐day stenting (C and D). (A and C) Digital microscopic images showing a
surface of strut covered by newly generated tissue. (B and D) SEM images showing disorganized tissue on struts.
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Figure 6. Anti‐CD34 antibody‐bound stents after 14‐day stenting. (A)Digital microscopic image showing stent struts embedded in thick tissue. (B
and C) SEM images showing tissue composed of multicellular aggregates. (D) SEM image showing endothelium‐like tissue.
Figure 7. Ki67‐positive cells in neointimal tissue on VEGF‐bound and anti‐CD34 antibody‐bound stent after 14‐day stenting. Note that the
proportion of proliferative cells, assessed by Ki67 staining (A), is signiﬁcantly higher in the neointimal tissue of the anti‐CD34 antibody‐bound
stents than that of the VEGF‐bound stents (B).
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clinical trials, these stents have not been therapeutically
effective, due to the high rate of target‐lesion failure
and stent thrombosis.18,19 In the present study, we
attempted to apply VEGF instead of anti‐CD34
antibody to facilitate formation of endothelium for
early repair of injured vessel walls. An ideal scenario
for vital formation of endothelium on stent struts is
highly selective in situ capture of EPCs from arterial
blood ﬂow and subsequent full endothelialization
during the early period after implantation. To achieve
this goal, we conducted a series of preliminary
studies15,16,20,21 prior to veriﬁcation of “proof‐of‐
concept” in an animal model as was done in the
present study. Based on these data, the main theme of
this study was to verify that EPCs are captured from
arterial blood ﬂow, and to determine the degree to
which endothelialization is promoted on a VEGF‐
bound platform. There are 2 possible pathways leading
to endothelialization on stent struts: capture of EPCs
circulating in arterial blood ﬂow and migration of ECs
from adjacent native tissue. Although we cannot
exclude a contribution of the latter pathway to
endothelialization, immunohistochemistry demon-
strates direct rapid capture of KDR‐positive cells on
stent struts, which were not contacted by native
endothelium in the bloodstream. Importantly, such
EPC capture occurs within 2 days after stenting. This is
also supported by ex vivo studies of ours21 and
others22,23 providing important proof in concept that
EPC adhesion occurs and high adhesion retention holds
under physiological levels of hydrodynamic shear
stress. Subsequently, endothelialization is completed
within 1–2 weeks after stenting proceeds (Figs. 3
and 4).
On the other hand, tissue generated on anti‐CD34
antibody‐bound stents exhibited quite disorganized
tissue architecture, composed of a mixture of multicel-
lular aggregates and endothelium‐like tissue (Figs. 5
and 6). Interestingly, the proportion of proliferating
cells in neointimal tissue was approximately 1.5 times
higher for anti‐CD34 antibody‐bound stents than for
VEGF‐bound stents (Fig. 8) associated with somewhat
increased neointimal thickness in comparison with that
in VEGF‐bound stents after 14‐day stenting. Although
we did not randomize stents for implantation, the
present results can provide the superiority of VEGF to
anti‐CD34 antibody‐bound stents for early endotheli-
alization. The study with implantation of 2 types of
stents in 1 swine will give more credible results than
those in the present study in terms of endothelial
coverage and intimal hyperplasia. Also, long‐term
implantation may further differentiate the neointimal
tissue architectures between these 2 types of stents.
Our previous study showed that the anti‐thrombo-
genic potential of human EPCs is almost half that of
human ECs, in terms of production of prostacyclin,
tissue plasminogen activator, and nitric oxide synthe-
tase.24 Furthermore, ex vivo EPC‐seeded small‐
diameter grafts exhibited thrombus‐free performances
in a canine carotid artery model,25 and ex vivo EPC‐
seeded stents performed well in vitro.24 These
observations suggest that cooperative action of a
prolonged matricine effect induced by VEGF bound
to the stent surface and the mechanotransduction effect
caused by continuous shear stress loading from arterial
blood ﬂow eventually accelerate differentiation and
endothelialization in the arterial bloodstream. Recently,
an anti‐VE‐cadherin antibody‐bound stent was shown
Figure 8. Microscopic images of cross‐sectional specimens of coronary arteries with (A) VEGF‐bound and (B) anti‐CD34 antibody‐bound stents
harvested after 14‐day stenting (hematoxylin–eosin staining).
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to capture endothelial‐lineage cells more selectively
than an anti‐CD34 antibody‐bound stent, resulting in
faster and higher quality endothelium formation.26,27
VE‐cadherin is expressed on cell surfaces of ECs at a
later stage of endothelialization, and VE‐cadherin
molecules engage in homophilic interactions at
adherens junctions in adjacent ECs. Although mecha-
nistic aspects of EPC capture at the cellular level may
differ, both types of stents might contribute to vital
endothelial architecture, and hopefully may provide
better choices for repair of diseased coronary arteries.
In the present study, we used healthy swine basically
without coronary atherosclerosis. Therefore, it may be
premature to transfer the present results into clinical
settings such as coronary artery disease. A study with
atherosclerotic swine models28 may resolve this issue
which is important for clinical application.
Conclusions
The present study demonstrates that in comparison to
anti‐CD34 antibody‐bound stents, VEGF‐bound stents
can achieve highly selective capture of EPCs followed
by accelerated natural endothelial tissue formation.
Rapid, high‐quality, and intact endothelium tissue
formation represents a promising therapeutic option for
cardiovascular stenting, although the further long‐term
follow‐up experiment is needed prior to clinical
application.
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